Abstract
The role of angiogenesis in haematological malignancies has been recently recognized. In these tumors, angiogenesis has been investigated predominantly in the bone marrow (BM) compartment where it appears to be regulated by multiple interactions between malignant cells and different cell populations present in the tumor microenvironment. Thus, angiogenesis represents a therapeutic target that opens new perspectives for the treatment of haematological malignancies. Cytokines are small proteins that mediate intercellular communications, thus regulating important cellular functions, such as immune responses and angiogenesis. Some cytokines show anti-angiogenic properties through different mechanisms; these cytokines can interfere directly with biological functions of endothelial cells and/or target tumor cells inhibiting their capability to stimulate formation of new microvessels that are essential for tumor growth and dissemination. In this review we will summarize the current knowledge about the role of cytokines as anti-angiogenic agents in cancer, focusing our attention on the anti-angiogenic activity of IL-12 family members in haematological malignancies.
Keywords: Angiogenesis, cytokines, cytokine receptors, haematological malignancies, acute myeloid leukemia, angiopoietin, B cell acute ymphoblastic leukemia, B cell chronic lymphocytic leukemia, bone marrow, chorioallantoid membrane, fibroblast growth factor, granulocyte colony stimulating factors, interferon, interleukin
Current Cancer Drug Targets
Title: Cytokines as Anti-Angiogenic Agents in Haematological Malignancies
Volume: 11 Issue: 9
Author(s): C. Cocco, E. Ferretti, I. Airoldi and V. Pistoia
Affiliation:
Keywords: Angiogenesis, cytokines, cytokine receptors, haematological malignancies, acute myeloid leukemia, angiopoietin, B cell acute ymphoblastic leukemia, B cell chronic lymphocytic leukemia, bone marrow, chorioallantoid membrane, fibroblast growth factor, granulocyte colony stimulating factors, interferon, interleukin
Abstract: The role of angiogenesis in haematological malignancies has been recently recognized. In these tumors, angiogenesis has been investigated predominantly in the bone marrow (BM) compartment where it appears to be regulated by multiple interactions between malignant cells and different cell populations present in the tumor microenvironment. Thus, angiogenesis represents a therapeutic target that opens new perspectives for the treatment of haematological malignancies. Cytokines are small proteins that mediate intercellular communications, thus regulating important cellular functions, such as immune responses and angiogenesis. Some cytokines show anti-angiogenic properties through different mechanisms; these cytokines can interfere directly with biological functions of endothelial cells and/or target tumor cells inhibiting their capability to stimulate formation of new microvessels that are essential for tumor growth and dissemination. In this review we will summarize the current knowledge about the role of cytokines as anti-angiogenic agents in cancer, focusing our attention on the anti-angiogenic activity of IL-12 family members in haematological malignancies.
Export Options
About this article
Cite this article as:
Cocco C., Ferretti E., Airoldi I. and Pistoia V., Cytokines as Anti-Angiogenic Agents in Haematological Malignancies, Current Cancer Drug Targets 2011; 11 (9) . https://dx.doi.org/10.2174/156800911798073096
DOI https://dx.doi.org/10.2174/156800911798073096 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adrenomedullin in Heart Failure: Molecular Mechanism and Therapeutic Implication
Current Hypertension Reviews Treatment of Diabetic Foot Ulcer: An Overview Strategies for Clinical Approach
Current Diabetes Reviews Refractory Angina Pectoris: Lessons from the Past and Current Perspectives
Current Pharmaceutical Design Subject Index to Volume 10
Current Medicinal Chemistry Antihypertensive Drug Treatment and Circadian Blood Pressure Rhythm: A Review of the Role of Chronotherapy in Hypertension
Current Pharmaceutical Design Merging Transport Data for Choroid Plexus with Blood-Brain Barrier to Model CNS Homeostasis and Disease More Effectively
CNS & Neurological Disorders - Drug Targets Parkinsons Disease: Genetics and Beyond
Current Neuropharmacology The Use of Infliximab in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Adrenal Insufficiency Caused by Locally Applied Glucocorticoids-Myth or Fact?
Current Medicinal Chemistry Supramolecular Chiro-Biomedical Aspect of β-Blockers in Drug Development
Current Drug Targets Oxytocin in the Heart Regeneration
Recent Patents on Cardiovascular Drug Discovery Diamidine Activity Against Trypanosomes: The State of the Art
Current Molecular Pharmacology Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy Therapeutic Agents for COVID-19: an Overview
Current Drug Therapy A Review on Phytochemistry and Pharmacology of Medicinal as well as Poisonous Mushrooms
Mini-Reviews in Medicinal Chemistry Angiotensin, The Hormone to be Blocked by Antithypertensive Drugs, and Perhaps Why They Dont Work
Current Vascular Pharmacology Antiplatelet Therapy in the Prevention of Coronary Syndromes: Mode of Action, Benefits, Drawbacks
Cardiovascular & Hematological Agents in Medicinal Chemistry Heart Failure in Minority Populations - Impediments to Optimal Treatment in Australian Aborigines
Current Cardiology Reviews Calorie Restriction and Dietary Restriction Mimetics: A Strategy for Improving Healthy Aging and Longevity
Current Pharmaceutical Design Chemoradiotherapy in Locally Advanced, Unresectable Non-Small Cell Lung Cancer
Reviews on Recent Clinical Trials